Compare PCRX & CCOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | CCOI |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2011 | N/A |
| Metric | PCRX | CCOI |
|---|---|---|
| Price | $26.12 | $22.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | ★ $32.86 | $30.25 |
| AVG Volume (30 Days) | 885.6K | ★ 1.3M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 18.35% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | $716,791,000.00 | ★ $907,233,000.00 |
| Revenue This Year | $6.24 | $4.50 |
| Revenue Next Year | $9.53 | $2.63 |
| P/E Ratio | $55.17 | ★ N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $18.18 | $15.96 |
| 52 Week High | $27.64 | $84.06 |
| Indicator | PCRX | CCOI |
|---|---|---|
| Relative Strength Index (RSI) | 56.85 | 51.24 |
| Support Level | $24.20 | $19.38 |
| Resistance Level | $26.48 | $22.86 |
| Average True Range (ATR) | 0.98 | 1.08 |
| MACD | -0.11 | 0.20 |
| Stochastic Oscillator | 68.10 | 83.24 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Cogent carries over one-fifth of the world's internet traffic on its network, providing high-capacity services to businesses. Cogent's corporate customers are in high-rise office buildings, where the firm provides two types of connections: dedicated internet access, which connects them to the internet, and virtual private networking, which offers an internal network for employees in different locations. Cogent's corporate customers are exclusively in North America and account for nearly half of the firm's revenue. Cogent's netcentric customers include internet service providers and content providers, to which Cogent provides internet transit. They hand traffic to Cogent in data centers and rely on Cogent to deliver it. About half of netcentric revenue is from outside the US.